Aliases & Classifications for Syncope

MalaCards integrated aliases for Syncope:

Name: Syncope 54 29 6

Summaries for Syncope

NINDS : 54 Syncope is a medical term used to describe a temporary loss of consciousness due to the sudden decline of blood flow to the brain. Syncope is commonly called fainting or “passing out.” If an individual is about to faint, he or she will feel dizzy, lightheaded, or nauseous and their field of vision may “white out” or “black out.”  The skin may be cold and clammy.  The person drops to the floor as he or she loses consciousness.  After fainting, an individual may be unconscious for a minute or two, but will revive and slowly return to normal.  Syncope can occur in otherwise healthy people and affects all age groups, but occurs more often in the elderly.  There are several types of syncope.  Vasovagal syncope usually has an easily identified triggering event such as emotional stress, trauma, pain, the sight of blood, or prolonged standing.  Carotid sinus syncope happens because of constriction of the carotid artery in the neck and can occur after turning the head, while shaving, or when wearing a tight collar.  Situational syncope happens during urination, defecation, coughing, or as a result of gastrointestinal stimulation.  Syncope can also be a symptom of heart disease or abnormalities that create an uneven heart rate or rhythm that temporarily affect blood volume and its distribution in the body.  Syncope isn’t normally a primary sign of a neurological disorder, but it may indicate an increased risk for neurologic disorders such as Parkinson’s disease, postural orthostatic tachycardia syndrome (POTS), diabetic neuropathy, and other types of neuropathy.  Certain classes of drugs are associated with an increased risk of syncope, including diuretics, calcium antagonists, ACE inhibitors, nitrates, antipsychotics, antihistamines, levodopa, narcotics, and alcohol.

MalaCards based summary : Syncope is related to brugada syndrome 1 and timothy syndrome. An important gene associated with Syncope is SLC6A2 (Solute Carrier Family 6 Member 2), and among its related pathways/superpathways are Transmission across Chemical Synapses and Human Embryonic Stem Cell Pluripotency. The drugs Dopamine and Fludrocortisone have been mentioned in the context of this disorder. Affiliated tissues include testes, heart and brain, and related phenotypes are cardiovascular system and muscle

Wikipedia : 75 Syncope, also known as fainting, is a loss of consciousness and muscle strength characterized by a fast... more...

Related Diseases for Syncope

Diseases related to Syncope via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Related Disease Score Top Affiliating Genes
1 brugada syndrome 1 10.4 SCN5A KCNH2
2 timothy syndrome 10.4 KCNQ1 KCNH2
3 long qt syndrome 9 10.3 SCN5A KCNJ2
4 third-degree atrioventricular block 10.3 SCN5A NPPB
5 left bundle branch hemiblock 10.2 SCN5A NPPB
6 long qt syndrome 13 10.2 SCN5A KCNQ1 KCNH2
7 long qt syndrome 12 10.2 SCN5A KCNQ1 KCNH2
8 long qt syndrome 3 10.2 SCN5A KCNQ1 KCNH2
9 cardiac conduction defect 10.2 SCN5A KCNQ1 KCNH2
10 ventricular fibrillation, paroxysmal familial, 1 10.2 SCN5A KCNQ1 KCNH2
11 jervell and lange-nielsen syndrome 1 10.2 SCN5A KCNQ1 KCNH2
12 brugada syndrome 10.1 SCN5A KCNQ1 KCNH2
13 sick sinus syndrome 10.1 TTN SCN5A
14 familial short qt syndrome 10.1 KCNQ1 KCNJ2 KCNH2
15 short qt syndrome 10.1 KCNQ1 KCNJ2 KCNH2
16 sudden infant death syndrome 10.1 SCN5A KCNQ1 KCNH2
17 oppositional defiant disorder 10.1 SLC6A2 DBH
18 atrial standstill 10.1 SCN5A NPPA
19 familial isolated dilated cardiomyopathy 10.1 TTN SCN5A ACTN2
20 catecholaminergic polymorphic ventricular tachycardia 10.0 SCN5A KCNJ2 KCNH2
21 hypertrophic cardiomyopathy 10.0 TTN SCN5A ACTN2
22 cocaine abuse 9.9 SLC6A2 DBH
23 ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy 9.8 SCN5A KCNQ1 KCNJ2 KCNH2
24 long qt syndrome 5 9.8 SCN5A KCNQ1 KCNJ2 KCNH2
25 long qt syndrome 9.8 SCN5A KCNQ1 KCNJ2 KCNH2
26 long qt syndrome 6 9.8 SCN5A KCNQ1 KCNJ2 KCNH2
27 andersen cardiodysrhythmic periodic paralysis 9.8 SCN5A KCNQ1 KCNJ2 KCNH2
28 cardiac arrhythmia 9.8 SCN5A KCNQ1 KCNJ2 KCNH2
29 long qt syndrome 2 9.8 SCN5A KCNQ1 KCNJ2 KCNH2
30 anterolateral myocardial infarction 9.8 NPPB NPPA
31 renal hypertension 9.8 NPPB DBH
32 long qt syndrome 1 9.8 SCN5A KCNQ1 KCNJ2 KCNH2
33 left ventricular noncompaction 9.8 TTN SCN5A KCNQ1 ACTN2
34 central sleep apnea 9.8 NPPB NPPA
35 syndrome of inappropriate antidiuretic hormone 9.8 NPPB NPPA
36 arrhythmogenic right ventricular cardiomyopathy 9.7 TTN SCN5A KCNH2 ACTN2
37 atrioventricular block 9.7 SCN5A NPPB KCNQ1 KCNH2
38 cardiac arrest 9.7 SCN5A NPPB KCNQ1 KCNH2
39 mitral valve stenosis 9.7 NPPB NPPA
40 idiopathic edema 9.7 NPPB NPPA
41 diastolic heart failure 9.7 NPPB NPPA
42 mitral valve insufficiency 9.6 NPPB NPPA
43 atrial standstill 1 9.6 TTN SCN5A NPPB ACTN2
44 pulmonary hypertension, primary, 1 9.6 NPPB NPPA
45 intrinsic cardiomyopathy 9.4 TTN SCN5A KCNQ1 KCNJ2 KCNH2
46 pericardial effusion 9.4 NPPB NPPA
47 heart conduction disease 9.3 SCN5A NPPB KCNQ1 KCNJ2 KCNH2
48 pure autonomic failure 9.2 NPPA GNB3 DBH
49 heart valve disease 9.2 NPPB NPPA
50 familial atrial fibrillation 9.1 SCN5A NPPA KCNQ1 KCNJ2 KCNH2

Graphical network of the top 20 diseases related to Syncope:

Diseases related to Syncope

Symptoms & Phenotypes for Syncope

MGI Mouse Phenotypes related to Syncope:

# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.56 DBH KCNH2 KCNJ2 KCNQ1 NPPA SCN5A
2 muscle MP:0005369 9.1 KCNH2 KCNJ2 KCNQ1 NPPA SCN5A TTN

Drugs & Therapeutics for Syncope

Drugs for Syncope (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 323)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
Fludrocortisone Approved, Investigational Phase 4 127-31-1 31378
Amlodipine Approved Phase 4 88150-42-9 2162
Losartan Approved Phase 4 114798-26-4 3961
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
Bisoprolol Approved Phase 4 66722-44-9 2405
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
Interferon beta-1b Approved Phase 4 145155-23-3
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
Polyestradiol phosphate Approved Phase 4 28014-46-2
Cefpirome Approved Phase 4 84957-29-9 5479539
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
Ticagrelor Approved Phase 4 274693-27-5 9871419
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
Ropinirole Approved, Investigational Phase 4 91374-21-9, 91374-20-8 5095 497540
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
Ramipril Approved Phase 4 87333-19-5 5362129
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
Midodrine Approved Phase 4 133163-28-7, 42794-76-3 4195
Silodosin Approved Phase 4 160970-54-7
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
Procainamide Approved Phase 4 51-06-9 4913
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
31 Adrenergic Agonists Phase 4
32 Adrenergic alpha-Agonists Phase 4
33 Dopamine Agents Phase 4
34 Natriuretic Agents Phase 4
35 diuretics Phase 4
36 Antiparkinson Agents Phase 4
37 Protective Agents Phase 4
38 Hormones Phase 4
39 Sodium Chloride Symporter Inhibitors Phase 4
40 calcium channel blockers Phase 4
41 Contraceptive Agents Phase 4
42 Fingolimod Hydrochloride Phase 4
43 (T,G)-A-L Phase 4
44 Interferon-beta Phase 4
Glatiramer Acetate Phase 4 147245-92-9 3081884
46 interferons Phase 4
47 Contraceptives, Oral Phase 4
48 Contraceptives, Oral, Combined Phase 4
49 Norgestimate, ethinyl estradiol drug combination Phase 4
50 Estradiol 3-benzoate Phase 4

Interventional clinical trials:

(show top 50) (show all 350)
# Name Status NCT ID Phase Drugs
1 Closed Loop Stimulation for Neuromediated Syncope Unknown status NCT01621464 Phase 4
2 Early Loop-Recorder in Suspected Arrhythmogenic Syncope Completed NCT00170261 Phase 4
3 ISSUE3: International Study on Syncope of Uncertain Etiology 3 Pacemaker Therapy for Patients With Asystolic Neurally-mediated Syncope Completed NCT00359203 Phase 4
4 A Randomized Clinical Trial of Fludrocortisone for Vasovagal Syncope: The Second Prevention of Syncope Trial (POST II) Completed NCT00118482 Phase 4 fludrocortisone acetate
5 Syncope: Pacing or Recording in the Later Years (SPRITELY) Completed NCT01423994 Phase 4
6 Physiologic Evaluation of Anomalous Right Coronary Artery Stenosis Completed NCT01133054 Phase 4
7 Propranolol for Syncope With Sympathoadrenal Imbalance Completed NCT00060866 Phase 4 Propranolol
8 The COMPAriSon of Systolic Blood Pressure Variability and Central Blood Pressure of Calcium Channel Blocker (Amlodipine) in Comparison With Angiotensin Receptor Blocker (Losartan) in Patients With Essential Hypertension Completed NCT01964079 Phase 4 Amlodipine;Losartan
9 Prospective, Open-labeled Trial in Patients With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea (PRISM) Completed NCT01074307 Phase 4 Low Dose Bisoprolol;High Dose Bisoprolol
10 A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS) Completed NCT01623596 Phase 4 Fingolimod;Disease Modifying therapy
11 Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration Completed NCT00280514 Phase 4 cefpirome and moxifloxacin administration
12 Post Marketing Surveillance Study for LDL Apheresis Using H.E.L.P. Therapy Completed NCT00916643 Phase 4
13 Language-based Learning Skills and ADHD: Impact of Treatment With Sustained-release Guanfacine Completed NCT01146002 Phase 4 Guanfacine (sustained release)
14 Reversal of the Anti-platelet Effects of Ticagrelor in Healthy Persons and Patients With Coronary Artery Disease Completed NCT02383771 Phase 4 Ticagrelor;Aspirin + Ticagrelor;Control;Aspirin + Ticagrelor
15 An Open-Label Prospective Study of Restless Legs Patients Switched to Ropinirole From Pramipexole to Help Determine the Equipotent Dose Completed NCT00344994 Phase 4 pramipexole
16 Effect of ACE-Inhibition on Microvascular Function in Women With Assessed Microvascular Dysfunction and No Obstructive Coronary Artery Disease Completed NCT02525081 Phase 4 Ramipril (ACE-inhibitor);placebo
17 Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Recruiting NCT02123056 Phase 4 Metoprolol;Matching Placebo
18 Effect of Pacemaker With Closed Loop Sensor on Quality of Life and Recurrence of Syncope in Patients With Neuromodulated Syncope Refractory to Medical Treatment: Randomized Double-blind Clinical Trial Recruiting NCT03876652 Phase 4
19 Effect of Pre-medication in Pain Measures on Office Hysteroscopy - Randomized Clinical Trial Recruiting NCT03506763 Phase 4 Placebo Oral + Placebo Oral;Diclofenac oral + Placebo Oral;Diclofenac oral + scopolamina oral
20 Randomized Evaluation of Beta Blocker and Angiotensin Converting Enzyme Inhibitor (ACEI) /Angiotensin Receptor Blocker (ARB) Treatment in MINOCA Patients. Recruiting NCT03686696 Phase 4 Beta blocker;ACEI;ARB
21 A Pilot and Feasibility Study to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Recruiting NCT02347111 Phase 4 Flecainide;Sotalol
22 Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV (Post 4) Active, not recruiting NCT01456481 Phase 4 midodrine hydrochloride;matching placebo
23 Comparison of Intravenous Amiodarone Versus Intravenous Procainamide for the Acute Treatment of Regular and Haemodynamically Well Tolerated Wide QRS Tachycardia (Probably of Ventricular Origen). The PROCAMIO Multicenter Study Terminated NCT00383799 Phase 4 iv Amiodarone;iv Procainamide
24 Comparison of Silodosin vs. Tamsulosin on Spontaneous Passage of Acutely Obstructing Ureteral Calculi in Medical Expulsive Therapy Terminated NCT02369744 Phase 4 Silodosin;Tamsulosin
25 Evaluate the Long-term (3 Months) Efficacy of L-threo DOPS (DroxiDopa) on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With Multiple System Atrophy (MSA). Comparative Study Versus Placebo Unknown status NCT02071459 Phase 2, Phase 3 L-Threo DOPS;placebo
26 Sequential E2 Levels Not Ovarian Maximal Diameter Estimates Were Correlated With Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome Unknown status NCT02823080 Phase 2, Phase 3 Cetrorelix
27 Randomized, Double-Blinded, Oseltamivir-and-Placebo-Controlled Clinical Study About Lingdancao Granules in the Treatment of Seasonal Influenza Unknown status NCT02662426 Phase 3 Lingdancao granules;analogous oseltamivir phosphate capsule;Oseltamivir phosphate capsule;analogous Lingdancao granules
28 Randomized Controlled Trial on Discontinuation of Vasoactive Drugs in Patients With Hypotensive Reflex Syncope Completed NCT02137278 Phase 3 Vasoactive drug therapies
29 Comparison of Ivabradine and Beta-blockers Administration in the Treatment of Inappropriate Sinus Tachycardia Completed NCT01657136 Phase 3 Ivabradine;Beta blocker
30 Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE) Completed NCT00000464 Phase 3 amiodarone;imipramine;mexiletine;procainamide;propafenone;quinidine;sotalol
31 CSP #563 - Prazosin and Combat Trauma PTSD (PACT) Completed NCT00532493 Phase 3 prazosin
32 Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14) Completed NCT01863186 Phase 3 Lofexidine HCl;Placebo;Open Label Lofexidine HCL
33 An Open-label Study, to Assess the Long-term Safety and Clinical Benefit of Droxidopa in Subjects With PAF, Dopamine Beta Hydroxylase Deficiency or Non-diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension Completed NCT00738062 Phase 3 Droxidopa;Placebo
34 A Multi-center, Double-blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients With Parkinson's Disease Completed NCT01176240 Phase 3 Droxidopa
35 Phase III, Multi-Center, Study to Assess the Clinical Effect of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic NOH Completed NCT00633880 Phase 3 Placebo;Droxidopa
36 Phase III, Multi-Center, Study to Assess the Clinical Effect of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic NOH Completed NCT00782340 Phase 3 Placebo;Droxidopa
37 Antiarrhythmics Versus Implantable Defibrillators (AVID) Completed NCT00000531 Phase 3 amiodarone amiodarone;sotalol
38 Comprehensive Approach to Lower Measured Blood Pressure (CALM-BP) - Results From a Randomized Controlled Trial Completed NCT00409149 Phase 3
39 A Randomized Double-blind Placebo Force-titration Controlled Study With Bisoprolol in Patients With Chronic Heart Failure Secondary to Chagas´ Cardiomyopathy. Completed NCT00323973 Phase 3 Bisoprolol
40 Randomized Noninferiority Study of an Antibacterial Envelope Alone Versus Envelope Plus Intraoperative Antibacterial Irrigant and Postoperative Antibiotics to Prevent Cardiac Implantable Electronic Device Infections in High-Risk Patients Recruiting NCT02809131 Phase 3 polymixin/bacitracin;cephalexin, or levofloxacin, or clindamycin;Saline
41 Liposomal Bupivacaine To Control Post-Operative Pain Following Buccal Mucosal Graft Harvesting Active, not recruiting NCT03720223 Phase 3 Liposomal Bupivacaine
42 A Double Blind Randomized Controlled Crossover Study to Systematically Assess the Efficacy and Safety of Intravenous Albumin Infusions in Severe Postural Orthostatic Tachycardia Syndrome Not yet recruiting NCT03365414 Phase 3 Normal Saline 0.9% Infusion Solution Bag
43 Intensive Blood Pressure Intervention in Stroke (IBIS) Trial Not yet recruiting NCT03585595 Phase 3
44 Benefit of Controlled Rehydration in Unexplained Syncope Terminated NCT00143754 Phase 3
45 BRD 06/2-D (Quidam) "Evaluation of the Interest of Oral Hydroquinidine Administration to Treat Patients With Brugada Syndrome, High Cardiac Arrhythmic Risk and Implanted With an Implantable Cardioverter Defibrillator" Terminated NCT00927732 Phase 3 hydroquinidine;placebo (sugar)
46 Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After ESWL Withdrawn NCT01560091 Phase 3 silodosin;Tamsulosin
47 Second Study on Cardio-neuromodulation in Humans Unknown status NCT02954666 Phase 2
48 ECG Device for Long QT Syndrome Screening in Newborns Unknown status NCT02412709 Phase 2
49 A Proof of Principle Study of Atomoxetine for the Prevention of Vasovagal Syncope (VVS): POST 6 Completed NCT02500732 Phase 2 Atomoxetine;Placebo
50 A Proof of Principal Study of Atomoxetine for the Prevention of Vasovagal Syncope (POST 6) Completed NCT02874937 Phase 2 Atomoxetine;Matching Placebo

Search NIH Clinical Center for Syncope

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Genetic Tests for Syncope

Genetic tests related to Syncope:

# Genetic test Affiliating Genes
1 Syncope 29

Anatomical Context for Syncope

MalaCards organs/tissues related to Syncope:

Testes, Heart, Brain, Skin, Lung, Prostate, Liver

Publications for Syncope

Articles related to Syncope:

(show top 50) (show all 15230)
# Title Authors PMID Year
A case of infective endocarditis associated with atopic dermatitis perioperatively treated with dupilumab. 38
30628496 2019
Characterization, epidemiological profile and risk factors for clinical outcome of infective endocarditis from a tertiary care centre in Turkey. 38
31364901 2019
Syncope due to tracheal adenoid cystic carcinoma. 38
31304017 2019
The Electrocardiogram: Still a Useful Tool in the Primary Care Office. 38
31378324 2019
When Is Syncope Arrhythmic? 38
31378326 2019
Feasibility of RA-LV pacing in patients with symptomatic left bundle branch block: a pilot study. 38
30963301 2019
Palpitation: Extended Electrocardiogram Monitoring: Which Tests to Use and When. 38
31378325 2019
Alpha-Blocker Use and the Risk of Hypotension and Hypotension-Related Clinical Events in Women of Advanced Age. 38
31327266 2019
Ruptured inferior vena cava aneurysm in the setting of mural vascular malformation: A case report. 38
30801724 2019
Identifying Common Predictors of Multiple Adverse Outcomes Among Elderly Adults With Type-2 Diabetes. 38
31356411 2019
The Evolving Management of Aortic Valve Disease: 5-Year Trends in SAVR, TAVR, and Medical Therapy. 38
31277791 2019
Exertional syncope caused by myocardial ischemia due to arterial steal syndrome in left internal mammary artery graft. 38
30870192 2019
Role of baseline 12‑lead ECG in predicting syncope caused by arrhythmia in patients investigated using an implantable loop recorder. 38
31304233 2019
Outpatient physical therapy cardiovascular assessment: Physical therapist perspective and experience. 38
29596007 2019
Assessment of the 2017 AHA/ACC/HRS Guideline Recommendations for Implantable Cardioverter-Defibrillator Implantation in Cardiac Sarcoidosis. 38
31431050 2019
Reappraisal of variants previously linked with sudden infant death syndrome: results from three population-based cohorts. 38
31043699 2019
Features associated with myocardial ischemia in anomalous aortic origin of a coronary artery: A Congenital Heart Surgeons' Society study. 38
31235351 2019
Balloon aortic valvuloplasty: Treatment of rapid deployment aortic valve replacement complicated by a paravalvular leak. 38
31212381 2019
Participation in thrill-seeking activities by patients with hypertrophic cardiomyopathy: Individual preferences, adverse events and physician attitude. 38
31152873 2019
Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids). 38
31411652 2019
The prognostic value of biventricular long axis strain using standard cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy. 38
31405582 2019
Automated extraction of sudden cardiac death risk factors in hypertrophic cardiomyopathy patients by natural language processing. 38
31160009 2019
A practical guide to active stand testing and analysis using continuous beat-to-beat non-invasive blood pressure monitoring. 38
31076939 2019
Exercise testing oversights underlie missed and delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia in young sudden cardiac arrest survivors. 38
30763784 2019
Sudden death in transposition of the great arteries with atrial switch surgery: Autopsy evidence of acute myocardial ischemia despite normal coronary arteries. 38
30808604 2019
Preparedness and attitudes towards medical emergencies in the dental office among Polish dentists. 38
30843612 2019
Introduction of portable bedside echocardiography to acute general medicine. 38
31387155 2019
Similar Cerebral Blood Flow and Autonomic Responses to Upright Tilt Test in Adult Patients With Different Hemodynamic Mechanisms Leading to Reflex Syncope. 38
31385853 2019
Gastric Emphysema: A Cannot-Miss Emergency Medicine Diagnosis. 38
28617713 2019
Swallow syncope: a case report and review of literature. 38
31391000 2019
Synergistic Bradycardia from Beta Blockers, Hyperkalemia, and Renal Failure. 38
31155316 2019
Pulmonary Embolism in Patients With Syncope: Horse or Zebra? 38
31395125 2019
Prevalence of Pulmonary Embolism in Patients With Syncope. 38
31395124 2019
Utility of autonomic testing for the efficient diagnosis and effective pharmacological management of neurogenic orthostatic hypotension. 38
31434666 2019
Mechanisms of tilt-induced vasovagal syncope in healthy volunteers and postural tachycardia syndrome patients without past history of syncope. 38
31250563 2019
Asystolic syncope - To pace or not to pace, that is the question. 38
31079972 2019
Driving Habits and Risk of Traffic Accidents among People with Ménière's Disease in Finland. 38
31287436 2019
Exploring the experiences of individuals with an insertable cardiac monitor: Making the decision for device insertion. 38
31399224 2019
Anaphylactic shock following a bite of a wild Kayan slow loris (Nycticebus kayan) in rural Sarawak, Malaysian Borneo. 38
31421666 2019
Comparison of clinical and electrophysiological characteristics between ictal and cardiac asystole encountered during video-EEG monitoring. 38
31371275 2019
[Update ESC Guideline Syncope 2018]. 38
31350745 2019
Pacemaker implantation in familial amyloid polyneuropathy: when and for whom? 38
30852744 2019
Clinical features and arrhythmic complications of patients with pediatric-onset arrhythmogenic right ventricular dysplasia. 38
31375646 2019
Going Beyond the Guidelines in Individualising the Use of Antihypertensive Drugs in Older Patients. 38
31175614 2019
Long-Term Radiotherapy-Induced Cardiac Complications: A Case Report. 38
31401643 2019
Prevalence and Predictors of Pulmonary Embolism in Hospitalized Patients with Syncope. 38
31375838 2019
Oculocardiac Reflex: An Underrecognized But Important Association With Orbital Trap Door Fractures. 38
31389903 2019
Vestibular neurons with direct projections to the solitary nucleus in the rat. 38
31166818 2019
Molecular genetic framework underlying pulmonary arterial hypertension. 38
31406341 2019
Meaningful and feasible composite clinical worsening definitions in paediatric pulmonary arterial hypertension: An analysis of the TOPP registry. 38
31072635 2019

Variations for Syncope

ClinVar genetic disease variations for Syncope:

# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 SCN5A NM_000335.4(SCN5A): c.1255C> T (p.Gln419Ter) single nucleotide variant Likely pathogenic rs1057518916 3:38647525-38647525 3:38606034-38606034
2 ACTL6A NM_004301.5(ACTL6A): c.1129C> T (p.Arg377Trp) single nucleotide variant Likely pathogenic rs868064163 3:179304340-179304340 3:179586552-179586552
3 MEFV NM_000243.2(MEFV): c.2084A> G (p.Lys695Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs104895094 16:3293403-3293403 16:3243403-3243403
4 KCNE3 NM_005472.4(KCNE3): c.248G> A (p.Arg83His) single nucleotide variant Conflicting interpretations of pathogenicity rs17215437 11:74168361-74168361 11:74457316-74457316
5 TTN NM_133379.5(TTN): c.13364A> G (p.Lys4455Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs142304137 2:179613763-179613763 2:178749036-178749036
6 ACTN2 NM_001103.3(ACTN2): c.1040C> T (p.Thr347Met) single nucleotide variant Conflicting interpretations of pathogenicity rs727504590 1:236902765-236902765 1:236739465-236739465

Expression for Syncope

Search GEO for disease gene expression data for Syncope.

Pathways for Syncope

Pathways related to Syncope according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
3 11.98 KCNQ1 KCNJ2 KCNH2 GNB3
Show member pathways
5 11.77 SCN5A KCNQ1 KCNH2 GNB3
Show member pathways
Show member pathways
11.11 SLC6A2 DBH
9 10.82 SLC6A2 DBH
10 10.78 NPPB NPPA
11 10.68 KCNQ1 KCNJ2

GO Terms for Syncope

Cellular components related to Syncope according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intercalated disc GO:0014704 9.26 SCN5A KCNJ2
2 T-tubule GO:0030315 9.16 SCN5A KCNJ2
3 Z disc GO:0030018 9.13 TTN SCN5A ACTN2
4 voltage-gated potassium channel complex GO:0008076 8.8 KCNQ1 KCNJ2 KCNH2

Biological processes related to Syncope according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 9.95 SCN5A KCNQ1 KCNJ2 KCNH2
2 transmembrane transport GO:0055085 9.94 SLC6A2 SCN5A KCNQ1 KCNH2
3 protein folding GO:0006457 9.81 NPPB NPPA GNB3
4 potassium ion transport GO:0006813 9.8 KCNQ1 KCNJ2 KCNH2
5 potassium ion transmembrane transport GO:0071805 9.79 KCNQ1 KCNJ2 KCNH2
6 regulation of ion transmembrane transport GO:0034765 9.78 SCN5A KCNQ1 KCNJ2 KCNH2
7 regulation of blood pressure GO:0008217 9.67 NPPB NPPA GNB3
8 sarcomere organization GO:0045214 9.65 TTN ACTN2
9 muscle filament sliding GO:0030049 9.65 TTN ACTN2
10 positive regulation of heart rate GO:0010460 9.63 NPPA KCNQ1
11 response to pain GO:0048265 9.63 SLC6A2 DBH
12 regulation of ventricular cardiac muscle cell membrane repolarization GO:0060307 9.63 SCN5A KCNQ1 KCNH2
13 regulation of blood vessel size GO:0050880 9.62 NPPB NPPA
14 membrane depolarization during action potential GO:0086010 9.61 SCN5A KCNH2
15 ventricular cardiac muscle cell action potential GO:0086005 9.61 SCN5A KCNQ1 KCNH2
16 cardiac muscle cell action potential involved in contraction GO:0086002 9.6 SCN5A KCNJ2
17 potassium ion export across plasma membrane GO:0097623 9.59 KCNQ1 KCNH2
18 regulation of cardiac muscle cell contraction GO:0086004 9.58 SCN5A KCNJ2
19 membrane repolarization during ventricular cardiac muscle cell action potential GO:0098915 9.58 KCNQ1 KCNH2
20 positive regulation of potassium ion transmembrane transport GO:1901381 9.58 KCNQ1 KCNJ2 KCNH2
21 membrane depolarization during cardiac muscle cell action potential GO:0086012 9.57 SCN5A KCNJ2
22 receptor guanylyl cyclase signaling pathway GO:0007168 9.56 NPPB NPPA
23 positive regulation of cardiac muscle contraction GO:0060452 9.55 NPPA KCNQ1
24 membrane repolarization GO:0086009 9.54 KCNQ1 KCNH2
25 regulation of membrane repolarization GO:0060306 9.54 KCNQ1 KCNJ2 KCNH2
26 cGMP biosynthetic process GO:0006182 9.52 NPPB NPPA
27 atrial cardiac muscle cell action potential GO:0086014 9.51 SCN5A KCNQ1
28 membrane repolarization during cardiac muscle cell action potential GO:0086013 9.5 KCNQ1 KCNJ2 KCNH2
29 cardiac muscle contraction GO:0060048 9.46 TTN SCN5A KCNQ1 KCNH2
30 membrane repolarization during action potential GO:0086011 9.43 KCNQ1 KCNJ2 KCNH2
31 regulation of atrial cardiac muscle cell membrane repolarization GO:0060372 9.13 SCN5A NPPA KCNQ1
32 regulation of heart rate by cardiac conduction GO:0086091 8.92 SCN5A KCNQ1 KCNJ2 KCNH2

Molecular functions related to Syncope according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 calmodulin binding GO:0005516 9.63 TTN SCN5A KCNQ1
2 ion channel binding GO:0044325 9.58 SCN5A KCNQ1 ACTN2
3 phosphatidylinositol-4,5-bisphosphate binding GO:0005546 9.5 KCNQ1 KCNJ2 ACTN2
4 structural constituent of muscle GO:0008307 9.49 TTN ACTN2
5 delayed rectifier potassium channel activity GO:0005251 9.48 KCNQ1 KCNH2
6 inward rectifier potassium channel activity GO:0005242 9.43 KCNJ2 KCNH2
7 voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization GO:1902282 9.37 KCNQ1 KCNH2
8 scaffold protein binding GO:0097110 9.33 SCN5A KCNQ1 KCNH2
9 hormone receptor binding GO:0051427 9.26 NPPB NPPA
10 voltage-gated ion channel activity GO:0005244 9.26 SCN5A KCNQ1 KCNJ2 KCNH2
11 voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization GO:0086008 8.8 KCNQ1 KCNJ2 KCNH2

Sources for Syncope

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....